Miragen Therapeutics Stock Price

-0.0135 (-1.44%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Miragen Therapeutics Inc MGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.023 -2.39% 0.9384 0.92 0.95 0.92 0.9614 00:00:01
Bid Price Ask Price Spread Spread % News
0.92 0.95 0.03 3.16% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
1,644 649,156 $ 0.9366547 $ 608,035 2,753,242 0.311 - 2.93
Last Trade Time Type Quantity Stock Price Currency
19:28:54 formt 10,035 $ 0.9249 USD

Miragen Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 49.81M 53.08M 52.74M $ 4.46M $ - -1.35 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Miragen Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MGEN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.101.100.921.00907,911-0.1616-14.69%
1 Month0.9571.710.851.223,055,753-0.0186-1.94%
3 Months0.551.710.50011.071,812,1170.388470.62%
6 Months0.652.930.3111.122,272,9640.288444.37%
1 Year2.152.930.3111.091,270,120-1.21-56.35%
3 Years13.0415.90990.3112.05548,105-12.10-92.8%
5 Years11.1118.000.3112.15489,936-10.17-91.55%

Miragen Therapeutics Description

Miragen Therapeutics Inc is a US-based clinical-stage biopharmaceutical company discovering and developing proprietary RNA (Ribonucleic acid)-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its clinical-stage product candidates include Cobomarsen (MRG-106), Remlarsen (MRG-201), MRG-229, and MRG-110. The company mainly focuses on developing such therapeutics which will target blood cancers, pathological fibrosis, and revascularization.

Your Recent History
Miragen Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.